NEW YORK – Everest Medicines on Tuesday announced that the first patient in China had been dosed with sacituzumab govitecan (Immunomedic's Trodelvy) in a registration trial evaluating the treatment for metastatic triple-negative breast cancer.
NEW YORK – Everest Medicines on Tuesday announced that the first patient in China had been dosed with sacituzumab govitecan (Immunomedic's Trodelvy) in a registration trial evaluating the treatment for metastatic triple-negative breast cancer.
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.